The ubiquitin-proteasome system: A potential therapeutic target for heart failure

Yaron D Barac1, Fabian Emrich2, Efrat Krutzwakd-Josefson1

  • 1Cardiothoracic Surgery Department, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Insights

The ubiquitin-proteasome system (UPS) impacts heart failure (HF) by regulating protein degradation, cardiac hypertrophy, and apoptosis. Targeting the UPS may reverse cardiac remodeling in HF patients.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Heart failure (HF) incidence is rising, increasing demand for cardiac assist devices.
  • The ubiquitin-proteasome system (UPS) is crucial for protein degradation and cellular regulation.

Purpose of the Study:

  • To review the role of the UPS in cardiac health and disease.
  • To discuss UPS involvement in pathological cardiac hypertrophy and its reversal.
  • To explore therapeutic strategies targeting the UPS for HF.

Main Methods:

  • Literature review of studies on the UPS in cardiac function and dysfunction.
  • Analysis of UPS impact on cardiac hypertrophy, apoptosis, and signaling pathways.
  • Examination of mechanical unloading effects on the UPS in HF.

Main Results:

  • The UPS plays a direct role in cardiac hypertrophy and HF.
  • UPS activity is altered by mechanical unloading, influencing cardiac remodeling.
  • The UPS regulates key cellular processes including apoptosis and β2-adrenergic signaling.

Conclusions:

  • The UPS is a critical regulator in cardiac health and HF.
  • Targeting the UPS presents a potential therapeutic strategy for reversing cardiac remodeling in HF.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
439
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
486
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K